This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down
by Zacks Equity Research
Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $169.61, moving -1.81% from the previous trading session.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Moderna (MRNA) Up on Its COVID Vaccine's Receipt of Full FDA Nod
by Zacks Equity Research
The FDA grants full approval to Moderna's (MRNA) mRNA-based COVID-19 vaccine, Spikevax, for individuals aged 18 years and above. Shares up.
Novavax's (NVAX) Shares Rise on FDA Filing for COVID Jab
by Zacks Equity Research
After a series of delays, Novavax (NVAX) finally files a regulatory application with the FDA seeking emergency use authorization of its COVID-19 vaccine.
Novavax (NVAX) Stock Rises on Deal for COVID-19 Jab in Israel
by Zacks Equity Research
Novavax (NVAX) enters into a supply agreement for its COVID-19 vaccine candidate, NVX-CoV2373, with Israel's Ministry of Health. Shares rise.
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Earnings Data to Flood Wall Street This Week
by Zacks Equity Research
Earnings Data to Flood Wall Street This Week.
Good Riddance to a Rough Trading Month
by Mark Vickery
It would be easy to forget we started out its first few trading days notching new all-time highs on both the Dow and the S&P 500.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and J&J
by Zacks Equity Research
Pfizer, BioNTech, Moderna and J&J are included in this analyst blog.
Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.
Moderna (MRNA) Starts Study for Omicron-Specific Booster Jab
by Zacks Equity Research
Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Moderna's (MRNA) Investors Losing Wealth: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) stock has been on a declining trend since August 2021 after a strong rally since the beginning of 2020.
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $157.30 in the latest trading session, marking a -1.73% move from the prior day.
4 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock in 2022
by Zacks Equity Research
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant
by Zacks Equity Research
Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.
Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022?
by Zacks Equity Research
Although Moderna's (MRNA COVID-19 vaccine sales are likely to rise, we expect pipeline updates to be the key catalyst for share price movement in 2022.
AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron
by Zacks Equity Research
Data from multiple studies support the use of AstraZeneca's (AZN) COVID vaccine booster against several variants of concern, including Omicron.
Ocugen's (OCGN) COVID-19 Booster Effective Against Omicron
by Zacks Equity Research
Ocugen's (OCGN) India-based partner announces robust neutralizing antibody responses against Omicron and Delta variants, following the administration of the booster dose of COVID-19 vaccine, Covaxin.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed at $222.89 in the latest trading session, marking a +0.68% move from the prior day.
Moderna (MRNA) Up on Plans to Get Omicron Booster Ready in 2022
by Zacks Equity Research
Moderna (MRNA) plans to begin clinical development of its Omicron-specific variant vaccine early in 2022 and expects to make it available for the public in the fall of 2022.
Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit
by Sanghamitra Saha
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.